Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials. (Q50871333)

From Wikidata

Jump to navigation Jump to search

scientific article published on 5 August 2015

Language	Label	Description	Also known as
English	Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials.	scientific article published on 5 August 2015

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26242380 AND SRC:MED&resulttype=core&format=json

20 February 2020

Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26242380 AND SRC:MED&resulttype=core&format=json

20 February 2020

phase I clinical trial

0 references

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26242380 AND SRC:MED&resulttype=core&format=json

20 February 2020

author name string

Mukul Minocha

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26242380 AND SRC:MED&resulttype=core&format=json

20 February 2020

Jonathan Q Tran

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26242380 AND SRC:MED&resulttype=core&format=json

20 February 2020

James P Sheridan

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26242380 AND SRC:MED&resulttype=core&format=json

20 February 2020

publication date

1 January 2016

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26242380 AND SRC:MED&resulttype=core&format=json

20 February 2020

Clinical Pharmacokinetics

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26242380 AND SRC:MED&resulttype=core&format=json

20 February 2020

55

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26242380 AND SRC:MED&resulttype=core&format=json

20 February 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26242380 AND SRC:MED&resulttype=core&format=json

20 February 2020

121-130

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26242380 AND SRC:MED&resulttype=core&format=json

20 February 2020

The biology of interleukin-2.

1 reference

https://api.crossref.org/works/10.1007/S40262-015-0305-Z

21 January 2018

Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy

1 reference

https://api.crossref.org/works/10.1007/S40262-015-0305-Z

21 January 2018

An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells

1 reference

https://api.crossref.org/works/10.1007/S40262-015-0305-Z

21 January 2018

Intermediate-affinity interleukin-2 receptor expression predicts CD56bright natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007/S40262-015-0305-Z

21 January 2018

Daclizumab therapy for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007/S40262-015-0305-Z

21 January 2018

Multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007/S40262-015-0305-Z

21 January 2018

Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1007/S40262-015-0305-Z

21 January 2018

Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource

1 reference

https://api.crossref.org/works/10.1007/S40262-015-0305-Z

21 January 2018

Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007/S40262-015-0305-Z

21 January 2018

Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey

1 reference

https://api.crossref.org/works/10.1007/S40262-015-0305-Z

21 January 2018

Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1007/S40262-015-0305-Z

21 January 2018

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

1 reference

https://api.crossref.org/works/10.1007/S40262-015-0305-Z

21 January 2018

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007/S40262-015-0305-Z

21 January 2018

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1007/S40262-015-0305-Z

21 January 2018

Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration.

1 reference

https://api.crossref.org/works/10.1007/S40262-015-0305-Z

21 January 2018

Population Pharmacokinetics/Dynamics*

1 reference

https://api.crossref.org/works/10.1007/S40262-015-0305-Z

21 January 2018

The number of human peripheral blood CD4 CD25high regulatory T cells increases with age.

1 reference

https://api.crossref.org/works/10.1007/S40262-015-0305-Z

21 January 2018

Functional regulatory T cells accumulate in aged hosts and promote chronic infectious disease reactivation

1 reference

https://api.crossref.org/works/10.1007/S40262-015-0305-Z

21 January 2018

Predictors of immunosuppressive regulatory T lymphocytes in healthy women

1 reference

https://api.crossref.org/works/10.1007/S40262-015-0305-Z

21 January 2018

Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/26242380

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody

1 reference

https://pubmed.ncbi.nlm.nih.gov/26242380

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40262-015-0305-Z

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26242380 AND SRC:MED&resulttype=core&format=json

20 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26242380 AND SRC:MED&resulttype=core&format=json

20 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50871333&oldid=2210541228"